A phase I/II study of ruxolitinib in combination with L-asparaginase, vincristine, and prednisone in adult patients with R/R ETP-ALL by Sichuan University is underway (NCT03613428). This evidence concerns the gene ASPG and acute lymphoblastic leukemia.